Open AccessUse of glucagon‐like peptide‐1 receptor agonists and bone fractures: A meta‐analysis of randomized clinical trials (胰高血糖素样肽‐1受体激动剂的使用与骨折的关系：一项对随机临床试验的meta分析)
Author(s) -
Mabilleau Guillaume,
Mieczkowska Aleksandra,
Chappard Daniel
Publication year - 2014
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.12102
Subject(s) - medicine , odds ratio , meta analysis , bone remodeling , randomized controlled trial , liraglutide , diabetes mellitus , type 2 diabetes mellitus , confidence interval , relative risk , type 2 diabetes , endocrinology
Patients with type 2 diabetes mellitus (T2DM) are at a higher risk of bone fractures independent of the use of antidiabetic medications. Furthermore, antidiabetic medications could directly affect bone metabolism. Recently, the use of dipeptidyl peptidase-4 inhibitors has been associated with a lower rate of bone fracture. The aim of the present meta-analysis was to assess whether patients with T2DM treated with glucagon-like peptide-1 receptor agonists (GLP-1Ra) present a lower incidence of bone fracture compared with patients using other antidiabetic drugs.